The National Blood Authority (NBA) has recently announced the outcomes of its tender for the provision of a number of imported plasma and recombinant products, replacing contracts for these products which expired on 30 June 2011.
These products, which are not manufactured in Australia, are used in the treatment of patients with bleeding disorders (ie, recombinant factor VIII (rFVIII), rFIX, activated prothrombin complex concentrate (APCC), plasma derived (pd) FVII, pdFXI and pdFXIII), protein C deficiency and for patients requiring intravenous Rh(D) immunoglobulin.
Further details regarding the outcome of the NBA’s tender process are available on their website.
